NCT07072988View on ClinicalTrials.gov

Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 19, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2027

Conditions

Myasthenia Gravis, Generalized

Interventions

DRUG

Efgartigimod

Administration of efgartigimod, a neonatal Fc receptor (FcRn) antagonist, given either intravenously (IV) or subcutaneously (SC) to treat patients with generalized Anti-AChR Myasthenia Gravis.

Trial Locations (1)

06000

RECRUITING

CHU de Nice, Nice

All Listed Sponsors

lead

Centre Hospitalier Universitaire de Nice

OTHER